<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00888914</url>
  </required_header>
  <id_info>
    <org_study_id>RT001-CL006LCL</org_study_id>
    <nct_id>NCT00888914</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines</brief_title>
  <official_title>A Phase 2, Double-Blind, Randomized, Parallel-Group, Controlled, Dose-Ranging, Multi-Center Study to Evaluate the Safety and Efficacy of RT001, a Botulinum Toxin Type A Topical Gel, to Treat Moderate to Severe Lateral Canthal Lines in Adults.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Revance Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Revance Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of RT001 to treat moderate
      to severe lateral canthal lines in adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multi-center study evaluates the safety and efficacy of four different doses of RT001
      compared to vehicle applied as a single, bilateral topical application in at least 60
      subjects with moderate to severe lateral canthal lines. Subjects will be randomized to one of
      the five treatment groups in a 1:1:1:1:1 ratio. Follow-up visits are scheduled through 28
      days post-treatment. The safety and efficacy of Cohort 1 (through the Day 14 visit) will be
      assessed prior to the decision to enroll subjects into Cohort 2 if additional doses or
      treatment regimens need to be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of subjects classified as exhibiting improvement via the Investigator Global Assessment at Smile from Baseline (Day 0) to End of Study (Day 28)</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of subjects classified as exhibiting improvement via the Investigator Global Assessment at Rest from Baseline (Day 0) to End of Study (Day 28)</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent AEs</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Lateral Canthal Lines</condition>
  <condition>Crow's Feet</condition>
  <condition>Facial Wrinkles</condition>
  <arm_group>
    <arm_group_label>Dose A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>RT001 Dose A; Active Comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>RT001 Dose B; Active Comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>RT001 Dose C; Active Comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>RT001 Dose D; Active Comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose E</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>RT001 Dose E; Vehicle Comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RT001</intervention_name>
    <description>RT001</description>
    <arm_group_label>Dose B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RT001</intervention_name>
    <description>RT001</description>
    <arm_group_label>Dose A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RT001</intervention_name>
    <description>RT001</description>
    <arm_group_label>Dose C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RT001</intervention_name>
    <description>RT001</description>
    <arm_group_label>Dose D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle Comparator</intervention_name>
    <description>Vehicle Comparator</description>
    <arm_group_label>Dose E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female or male; 30 to 55 years of age

          -  Bilateral lateral canthal lines rated as moderate or advanced

          -  Willing to refrain from receiving facial fillers, laser treatments, use of any product
             that affects remodeling or a product that may cause an active dermal response in the
             treatment area beginning at Screening through End of Study

          -  Women of childbearing potential must be practicing and willing to continue to use an
             effective method of birth control during the course of the study

        Exclusion Criteria:

          -  Muscle weakness or paralysis in the area receiving study treatment

          -  Active skin disease or irritation at the treatment areas

          -  Undergone any procedures that may affect the lateral canthal region during the past 12
             months prior to Screening

          -  Previous treatment with botulinum toxin (any serotype) in the head or neck area within
             9 months prior to Baseline (Day 0)

          -  Use of a topical steroid on either of the treatment areas or use of medications that
             suppress the immune system 30 days prior to Screening and continuing through End of
             Study (Day 28)

          -  Any abnormality on the electrocardiogram (ECG) at Screening or any history of
             clinically significant arrhythmia, unstable angina, myocardial infarction or
             congestive heart failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Richard G. Glogau, MD</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Head and Neck Surgical Group</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aesthetic Plastic Surgery</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Surgery and Laser Center</name>
      <address>
        <city>White Plains</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2009</study_first_submitted>
  <study_first_submitted_qc>April 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2009</study_first_posted>
  <disposition_first_submitted>September 23, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>September 23, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 28, 2010</disposition_first_posted>
  <last_update_submitted>October 25, 2013</last_update_submitted>
  <last_update_submitted_qc>October 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lateral Canthal Lines</keyword>
  <keyword>Crow's Feet</keyword>
  <keyword>Facial Wrinkles</keyword>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

